United States· US:55513-004_7023e5d7-0f00-4fa4-8223-fa77bee46feb
ARANESP
A darbepoetin alfa product containing darbepoetin alfa, registered in United States by Amgen, Inc. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Darbepoetin alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA02 (darbepoetin alfa), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Darbepoetin alfa · ATC B03XA02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of darbepoetin alfa costs, country by country.
Normalised to the WHO defined daily dose (4.5 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Darbepoetin alfa · price per daily dose (4.5 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$12.85
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DARBEPOETIN ALFA
- Manufacturer
- Amgen, Inc
- Country
- United States (US)
- ATC code
- B03XA02
- ATC class
- Darbepoetin alfa
- Defined daily dose
- 4.5 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 19, 2026
Packs & prices · 2
- ndc1155513004044 VIAL, SINGLE-DOSE in 1 PACKAGE (55513-004-04) / 1 mL in 1 VIAL, SINGLE-DOSE (55513-004-01)
- ndc1155513-004-04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
18 interactions on record for darbepoetin alfa.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Darbepoetin alfa · interactions on record
18 records
- 5 severe
- 3 moderate
- 10 minor
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Darbepoetin alfa in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaARANESPAmgen Europe B.V., Breda
- FinlandAranespAmgen Europe B.V.
- Japanダルベポエチンアルファ（遺伝子組換え）協和キリンフロンティア
- SpainARANESP 10 microgramos SOLUCION INYECTABLE EN JERINGA PRECARGADAAmgen Europe B.V.
- IcelandAranespAmgen Europe B.V.*
- SwedenAranesp 10 mikrogram Injektionsvätska, lösning i förfylld injektionspennaAmgen Europe B.V.
- BelgiumAranesp 10 µg/0.4 mlAmgen Europe
- NetherlandsAranesp 10 microgram, oplossing voor injectie in een voorgevulde pen (SureClick)Amgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Aranesp
- Norway · Aranesp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d61e1720-396d-447d-afbe-3a79bb61950a GET /v1/drugs/d61e1720-396d-447d-afbe-3a79bb61950a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS; SUBCUTANEOUS",
"source": "ndc",
"strength": "60",
"substance": "DARBEPOETIN ALFA",
"productndc": "55513-004",
"dosage_form": "SOLUTION",
"dea_schedule": null,
"strength_unit": "ug/mL",
"application_number": "BLA103951",
"marketing_category": "BLA"
}See everything about darbepoetin alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.